% | $
Quotes you view appear here for quick access.

Enzo Biochem Inc. Message Board

  • auagboy auagboy Aug 6, 2013 10:41 AM Flag

    $3.5-$4 buyout?

    patent portfolio + $80M cash = $150M

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ENZ is like a Mini Johnson & Johnson company. ENZO has many different products. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. ENZO has some real good drugs in their pipeline. Expect to hear about them more.

      Something to consider: ENZO has many products in the works. I wouldn't be surprised if some day they may be merged or be bought. ENZO could also sell off their divisions separately, or continue to grow them bigger and IPO them into separate companies. ENZO also continues to receive royalties from past patent infringements and license fees. Expect a lot more in the future as they have a whole list of companies they are going after, big and small, who have not paid a license fee and have infringed on their patent.

      Yes ENZ patents are worth many pots of gold and so is their portfolio and future growth.

      Here's a short Overview of their company

      Enzo Biochem, Inc. (Enzo), is an integrated life sciences and biotechnology company. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. Enzo focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. The Company has developed a portfolio of technologies with a variety of research, diagnostic and therapeutic applications. Enzo Clinical Labs segment is a regional clinical laboratory serving the New York, New Jersey and Eastern Pennsylvania medical communities. The Company's Enzo Life Sciences manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers world-wide. The Company's Enzo Therapeutics segment is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

      Sentiment: Strong Buy

6.18-0.070(-1.12%)May 27 4:02 PMEDT